Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Share News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Cyanconnode, Rosslyn Data rise on contract wins

Mon, 22nd Aug 2022 11:03

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

Cyanconnode Holdings PLC, up 29% at 19.00 pence, 12-month range 11.00p-29.85p. The narrowband radio frequency smart mesh networks firm says Indian subsidiary has received its largest-ever order. CyanConnode India Pvt Ltd has received an order from Genus Power Infrastructures Ltd for one million Omnimesh modules, together with advanced metering infrastructure, standards-based hardware, Omnimesh head-end software, perpetual license and a support and maintenance contract. The support and maintenance contract runs for eight years, starting upon completion of the installation phase.

----------

Rosslyn Data Technologies PLC, up 12% at 2.36p, 12-month range 1.50p-5.98p. The data management and analytics service provider wins first enterprise customer through partnership with indirect procurement service provider Chain IQ Group AG. Says initial contract is "of relatively small monetary value" but expects further contracts to come from partnership. Chief Executive Paul Watts says deal highlights value of partnership with Chain IQ.

----------

Open Orphan PLC, up 5.9% at 11.91p, 12-month range 10.00p-27.75p. The pharmaceutical services firm says subsidiary hVIVO Ltd has won a GBP10.4 million contract. Open Orphan says the contract has been signed with an "existing top five global pharmaceutical client". This is the third human challenge contract signed with the client, it adds.

----------

AIM - LOSERS

----------

Artemis Resources Ltd, down 11% at 2.05p, 12-month range 1.44p-5.00p. The miner says no significant nickel or copper results are found in laboratory analyses of samples from the first drill hole at the Osborne nickel prospect. Further, in a separate statement regarding its Greater Carlow project, holes ARC395 and ARC396 "did not return any significant mineralisation, in line with the offset of the lodes already discovered by holes ARC403 and ARC404," the Perth-based miner with gold, copper and cobalt projects in Australia adds.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
14 Dec 2020 11:38

Open Orphan upbeat on progress with nasal Covid-19 vaccine

(Sharecast News) - Specialist pharmaceuticals contract research organisation Open Orphan announced on Monday that the first in-human study of the Codagenix intranasal SARS-CoV-2 vaccine candidate for Covid-19 had gained approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA).

Read more
24 Nov 2020 16:27

UK EXECUTIVE CHANGE SUMMARY: Ocean Wilson Long-Time Finance Head Exits

UK EXECUTIVE CHANGE SUMMARY: Ocean Wilson Long-Time Finance Head Exits

Read more
19 Nov 2020 21:18

IN BRIEF: Open Orphan To Lead Challenge Agent Development Consortium

IN BRIEF: Open Orphan To Lead Challenge Agent Development Consortium

Read more
5 Nov 2020 16:32

IN BRIEF: Open Orphan Wins GBP2.5 Million Contract For Influenza Study

IN BRIEF: Open Orphan Wins GBP2.5 Million Contract For Influenza Study

Read more
30 Oct 2020 11:30

Open Orphan secures new two-year contract with German client

(Sharecast News) - Pharmaceutical services company Open Orphan announced a new two-year contract with an unnamed tier 1 Germany-based pharmaceutical company on Friday.

Read more
30 Oct 2020 11:07

Open Orphan Inks Two-Year Contract With Tier 1 German Pharma Company

Open Orphan Inks Two-Year Contract With Tier 1 German Pharma Company

Read more
20 Oct 2020 15:59

IN BRIEF: Open Orphan To Develop Covid Study Model For UK Government

IN BRIEF: Open Orphan To Develop Covid Study Model For UK Government

Read more
20 Oct 2020 09:49

Open Orphan to assist UK govt in Covid-19 study

(Sharecast News) - Pharmaceutical services company Open Orphan has signed a contract with the UK Government that will see the firm assist in the development of a Covid-19 human challenge study model to safely speed up the development of an efficacious vaccine.

Read more
16 Oct 2020 15:24

IN BRIEF: Open Orphan In Talks With UK Government Over Corona Study

IN BRIEF: Open Orphan In Talks With UK Government Over Corona Study

Read more
16 Oct 2020 08:57

Open Orphan continues talks over coronavirus challenge study

(Sharecast News) - Open Orphan updated the market on its talks with the UK government and other partners for a coronavirus challenge study in the UK on Friday, confirming that "advanced negotiations" were ongoing.

Read more
30 Sep 2020 18:37

UK EARNINGS SUMMARY: Itaconix 2019 Loss Narrows On Strong Revenue Rise

UK EARNINGS SUMMARY: Itaconix 2019 Loss Narrows On Strong Revenue Rise

Read more
28 Sep 2020 19:34

IN BRIEF: Open Orphan Wins GBP4.3 Million Human Viral Study Contract

IN BRIEF: Open Orphan Wins GBP4.3 Million Human Viral Study Contract

Read more
24 Sep 2020 17:35

UK TRADING UPDATE SUMMARY: Personal Group Lauds Royal Mail Contract

UK TRADING UPDATE SUMMARY: Personal Group Lauds Royal Mail Contract

Read more
22 Sep 2020 19:35

IN BRIEF: Open Orphan Lauds Venn's Clinical Study Support Contract Win

IN BRIEF: Open Orphan Lauds Venn's Clinical Study Support Contract Win

Read more
22 Sep 2020 09:43

Open Orphan subsidiary wins 'important' new contract

(Sharecast News) - Pharmaceutical contract research organisation Open Orphan secured an "important" new contract to support an unnamed European client via its French subsidiary, Venn Life Sciences.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.